Congestion as a Therapeutic Target in Acute Heart Failure Syndromes

Progress in Cardiovascular Diseases

Volumn 52, Issue 5, 2010, Pages 383-392

  Goldsmith, Steven R ^a   Brandimarte, Filippo ^b   Gheorghiade, Mihai ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Adenosine antagonists; Diuretics; Heart failure; Ultrafiltration; Vasopressin antagonists

Indexed keywords

ADENOSINE A1 RECEPTOR ANTAGONIST; CONIVAPTAN; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; ENDOTHELIN RECEPTOR ANTAGONIST; FUROSEMIDE; GLYCERYL TRINITRATE; HYDROCHLOROTHIAZIDE; INOTROPIC AGENT; ISTAROXIME; LEVOSIMENDAN; LOOP DIURETIC AGENT; METOLAZONE; MILRINONE; NATRIURETIC FACTOR; NESIRITIDE; NITRATE; PLACEBO; RELAXIN; ROLOFYLLINE; TOLVAPTAN; UNCLASSIFIED DRUG; VASODILATOR AGENT; VASOPRESSIN ANTAGONIST; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR ANTAGONIST;

ACUTE HEART FAILURE; ADD ON THERAPY; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG MEGADOSE; DRUG TARGETING; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HYPEREMIA; HYPOTENSION; LOW DRUG DOSE; PATHOPHYSIOLOGY; TREATMENT FAILURE; ULTRAFILTRATION;

ACUTE DISEASE; ADENOSINE; DIURESIS; DIURETICS; EDEMA; EDEMA, CARDIAC; HEART FAILURE; HEMOFILTRATION; HORMONE ANTAGONISTS; HUMANS; KIDNEY DISEASES; PULMONARY EDEMA; SYNDROME; TREATMENT OUTCOME; VASODILATOR AGENTS; VASOPRESSINS;

EID: 77649284509     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2009.11.005     Document Type: Article

References (57)

1. Gheorghiade M., Zannad F., Sopko G., et al. International Working Group on Acute heart Failure Syndromes. Acute heart failure syndromes: current state and framework for future research. Circulation 112 (2005) 3958-3968
2. Adams Jr. K.F., Yddin N., and Patterson J.H. Cardiac troponin and outcome in acute heart failure. N Engl J Med 358 (2008) 2117-2126
3. Klein L., Massie B.M., Leimberger J.D., et al. Admission or Changes in Renal Function During Hospitalization for Worsening Heart Failure Predict Postdischarge Survival: Results From the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). Circ Heart Fail 1 (2008) 25-33
4. Forman D.E., Butler J., Wang Y., et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 43 (2004) 61-67
5. Costanzo M.R., Guglin M.E., Saltzberg M.T., et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 49 (2007) 675-683
6. Adams Jr. K.F., Fonarow G.C., Emerman C.L., et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149 (2005) 209-216
7. Gheorghiade M., Abraham W.T., Albert N.M., et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 296 (2006) 2217-2226
8. Fonarow G.C., and Corday E. Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry. Heart Fail Rev 9 (2004) 179-185
9. Weber K.T. Furosemide in the long-term management of heart failure: the good, the bad, and the uncertain. J Am Coll Cardiol 44 (2004) 1308-1310
10. Hasselblad V., Gattis S.W., Shah M.R., et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 9 (2007) 1064-1069
11. Dormans T.P., Huige R.M., and Gerlag P.G. Chronic intermittent haemofiltration and haemodialysis in end stage chronic heart failure with oedema refractory to high dose frusemide. Heart 75 (1996) 349-351
12. Sharma A., Hermann D.D., and Mehta R.L. Clinical benefit and approach of ultrafiltration in acute heart failure. Cardiology 96 (2001) 144-154
13. Marenzi G., Lauri G., Grazi M., et al. Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure. J Am Coll Cardiol 38 (2001) 963-968
14. Rimondini A., Cipolla C., Della Bella P., et al. Hemofiltration as short-term treatment for refractory congestive heart failure. Am J Med 83 (1987) 43-48
15. Jaski B.E., Ha J., Denys B.G., et al. Peripherally inserted veno-venous ultrafiltration for rapid treatment of volume overloaded patients. J Card Fail 9 (2003) 227-231
16. Bart B.A., Boyle A., Bank A.J., et al. Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial. J Am Coll Cardiol 46 (2005) 2043-2046
17. Bart B.A., Fang J.C., Guglin M., et al. Changes in GFR, BUN and BUN/creatinine during treatment of heart failure and volume overload with ultrafiltration or intravenous diuretics. J Am Coll Cardiol 51 10 Suppl A (2008) A48
18. Firth J.D., Raine A.E., and Ledingham J.G. Raised venous pressure: a direct cause of renal sodium retention in oedema. Lancet 1 (1988) 1033-1035
19. Bart B.A., Goldsmith S.R., and Boyle A. Improvement in cardiorenal syndrome with ultrafiltration. J Card Fail (2009) [in press]
20. Bart B.A., Insel J., Goldstein M.M., et al. The improved outcomes following ultrafiltration versus intravenous diuretics in UNLOAD are not solely due to increased weight loss in the ultrafiltration group. J Cardiac Fail 13 Suppl 2 (2007) S188
21. Verbalis J.G. Vasopressin V2 receptor antagonists. J Mol Endocrinol 29 (2002) 1-9
22. Konstam M.A., Gheorghiade M., Burnett Jr. J.C., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 297 (2007) 1319-1331
23. Gheorghiade M., Konstam M.A., Burnett Jr. J.C., et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA 297 (2007) 1332-1343
24. Gheorghiade M., Gattis W.A., O'connor C.M., et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 291 (2004) 1963-1971
25. Goldsmith S.R., Haught H., Barve A., et al. Efficacy and safety of conivaptan in acute decompensated heart failure, a dose ranging pilot study. Heart Fail Rev 14 (2009) 1382-4147
26. Francis G.S., Siegel R.M., Goldsmith S.R., et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med 103 (1985) 1-6
27. Udelson J.E., Smith W.B., Hendrix G.H., et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104 (2001) 2417-2423
28. Udelson J.E., Orlandi C., Ouyang J., et al. Acute hemodynamic effects of tolvaptan, a vasopressin v2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol 52 (2008) 1540-1545
29. Costello-Boerrigter L.C., Smith W.B., Boerrigter G., et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 290 (2006) F273-F278
30. Rossi J., Bayram M., Udelson J.E., et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Card Care 9 (2007) 82-86
31. Weihprecht H., Lorenz J.N., Briggs J.P., et al. Synergistic effects of angiotensin and adenosine in the renal microvasculature. Am J Physiol 266 2 Pt 2 (1994) F227-F239
32. Thomson S., Bao D., Deng A., et al. Adenosine formed by 5′-nucleotidase mediates tubuloglomerular feedback. J Clin Invest 106 (2000) 289-298
33. Dittrich H.C., Gupta D.K., Hack T.C., et al. The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. J Card Fail 13 (2007) 609-617
34. Givertz M.M., Massie B.M., Fields T.K., et al. The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol 50 (2007) 1551-1560
35. Greenberg B., Thomas I., Banish D., et al. Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo-controlled, dose-escalation study. J Am Coll Cardiol 50 (2007) 600-606
36. Gottlieb S.S., Brater D.C., Thomas I., et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 105 (2002) 1348-1353
37. Gottlieb S.S., Skettino S.L., Wolff A., et al. Effects of BG9719 (CVT-124), an A1-Adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. J Am Coll Cardiol 35 (2000) 56-59
38. Metra M.O.C., Massie B., Cotter G., et al. PROTECT Study: effects of rolofylline in patients with acute heart failue syndrome and renal impairment. Eur Heart J (2009)
39. Cotter G., Metzkor E., Kaluski E., et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 351 (1998) 389-393
40. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 287 (2002) 1531-1540
41. Gheorghiade M., Gattis S.W., Adams Jr. K.F., et al. The Pilot Randomized Study of Nesiritide Versus Dobutamine in Heart Failure (PRESERVD-HF). Am J Cardiol 96 (2005) 18G-25G
42. Sackner-Bernstein J.D., Skopicki H.A., and Aaronson K.D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111 (2005) 1487-1491
43. Sackner-Bernstein J.D., Kowalski M., Fox M., et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293 (2005) 1900-1905
44. McMurray J.J., Teerlink J.R., Cotter G., et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 298 (2007) 2009-2019
45. Teerlink J.R., Metra M., Felker G.M., et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 373 (2009) 1429-1439
46. Cuffe M.S., Califf R.M., Adams Jr. K.F., et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287 (2002) 1541-1547
47. Mebazaa A., Nieminen M., Packer M., et al. Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure: the SURVIVE randomized trial. JAMA 297 (2007) 1883-1891
48. Packer M., Colucci W.S., Fisher L., et al. Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE 1 study. J Card Fail 9 (2003) S61
49. Packer M. The Rancomized multicenter EValuation of Intraveneous leVosimendan Efficacy-2 (REVIVE-2) trial. Late breaking clinical trials. American Heart Association, Annual Scientific Session, Dallas TX, November 13-16, 2005 (2005)
50. Felker G.M., Benza R.L., Chandler A.B., et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 41 (2003) 997-1003
51. Costello-Boerrigter L.C., Boerrigter G., Harty G.J., et al. Coadministration of the Vasopressin-2 Receptor Antagonist Tolvaptan and B-Type Natriuretic Peptide Enhances Water and Sodium Excretion without Adversely Affecting Renal or Neurohumoral Function in Experimental Congestive Heart Failure. J Card Fail (2007) S144
52. Elkayam U., Ng T.M., Hatamizadeh P., et al. Renal vasodilatory action of dopamine in patients with heart failure: magnitude of effect and site of action. Circulation 117 (2008) 200-205
53. Lisy O., Huntley B.K., McCormick D.J., et al. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol 52 (2008) 60-68
54. Guazzi M., Samaja M., Arena R., et al. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 50 (2007) 2136-2144
55. Ghali J.K., Smith W.B., Torre-Amione G., et al. A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function. Am J Cardiol (2007) 47A-56A
56. Gheorghiade M., Blair J.E., Filippatos G.S., et al. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. J Am Coll Cardiol 51 (2008) 2276-2285
57. Hermiller J.B., Magorien R.D., Leithe M.E., et al. Clonidine in congestive heart failure: a vasodilator with negative inotropic effects. Am J Cardiol 51 (1983) 791-795